Lauren Merendino's most recent trade in Day One Biopharmaceuticals Inc was a trade of 3,927 Common Stock done at an average price of $6.3 . Disclosure was reported to the exchange on May 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 6.26 per share. | 15 May 2025 | 3,927 | 35,161 | - | 6.3 | 24,575 | Common Stock |
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 3,687 | 51,626 | - | - | Restricted Stock Unit (RSU) | |
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 3,687 | 39,088 | - | - | Common Stock | |
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 3,687 | 35,401 | - | - | Common Stock | |
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 3,687 | 36,878 | - | - | Restricted Stock Unit (RSU) | |
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 3,162 | 28,464 | - | - | Restricted Stock Unit (RSU) | |
| Day One Biopharmaceuticals... | Lauren Merendino | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 3,162 | 31,714 | - | - | Common Stock | |
| Essa Pharma Inc | Lauren Merendino | Director | 25 Mar 2024 | 25,000 | 25,000 | - | - | Options |